Molecule Details
| InChIKey | LFQDNHWZDQTITF-UHFFFAOYSA-N |
|---|---|
| Compound Name | Tavaborole |
| Canonical SMILES | OB1OCc2cc(F)ccc21 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 6.84 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB09041 |
|---|---|
| Drug Name | Tavaborole |
| CAS Number | 174671-46-6 |
| Groups | approved |
| ATC Codes | D01AE24 |
| Description | Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential ... |
Categories: Anti-Infective Agents Antifungal Agents Antifungals for Dermatological Use Antifungals for Topical Use Dermatologicals Oxaborole Antifungal Protein Synthesis Inhibitors
Cross-references: BindingDB: 50370987 ChEBI: 77942 CHEMBL443052 ChemSpider: 9674047 D10169 PubChem:11499245 PubChem:310264989 RxCUI: 1543173 Wikipedia: Tavaborole ZINC: ZINC000169990691
Target Activities (3)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| P00918 | CA2 | Homo sapiens | Human | PF00194 | 6.3 | Ki | ChEMBL;BindingDB |
| Q6FTL6 | NCE103 | Candida glabrata (strain ATCC 2001 / BCRC 20586 / JCM 3761 / NBRC 0622 / NRRL Y-65 / CBS 138) | Pathogen | PF00484 | 7.1 | Ki | ChEMBL;BindingDB |
| Q3I4V7 | CAN2 | Cryptococcus neoformans | Pathogen | PF00484 | 7.0 | Ki | ChEMBL;BindingDB |
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| A0A178ESV1 | A0A178ESV1 | leucine--tRNA ligase | inhibitor | targets |